297 related articles for article (PubMed ID: 38791247)
1. Liquid Biopsies as Non-Invasive Tools for Mutation Profiling in Multiple Myeloma: Application Potential, Challenges, and Opportunities.
Heestermans R; Schots R; De Becker A; Van Riet I
Int J Mol Sci; 2024 May; 25(10):. PubMed ID: 38791247
[TBL] [Abstract][Full Text] [Related]
2. Liquid biopsies for multiple myeloma in a time of precision medicine.
Ferreira B; Caetano J; Barahona F; Lopes R; Carneiro E; Costa-Silva B; João C
J Mol Med (Berl); 2020 Apr; 98(4):513-525. PubMed ID: 32246161
[TBL] [Abstract][Full Text] [Related]
3. Liquid biopsy: an evolving paradigm for the biological characterisation of plasma cell disorders.
Mithraprabhu S; Chen M; Savvidou I; Reale A; Spencer A
Leukemia; 2021 Oct; 35(10):2771-2783. PubMed ID: 34262132
[TBL] [Abstract][Full Text] [Related]
4. Sensitivity, specificity, and accuracy of molecular profiling on circulating cell-free DNA in refractory or relapsed multiple myeloma patients, results of MM-EP1 study.
Quivoron C; Michot JM; Danu A; Lecourt H; Saada V; Saleh K; Vergé V; Cotteret S; Bernard OA; Ribrag V
Leuk Lymphoma; 2024 Jun; 65(6):789-799. PubMed ID: 38433500
[TBL] [Abstract][Full Text] [Related]
5. Whole-exome sequencing of cell-free DNA and circulating tumor cells in multiple myeloma.
Manier S; Park J; Capelletti M; Bustoros M; Freeman SS; Ha G; Rhoades J; Liu CJ; Huynh D; Reed SC; Gydush G; Salem KZ; Rotem D; Freymond C; Yosef A; Perilla-Glen A; Garderet L; Van Allen EM; Kumar S; Love JC; Getz G; Adalsteinsson VA; Ghobrial IM
Nat Commun; 2018 Apr; 9(1):1691. PubMed ID: 29703982
[TBL] [Abstract][Full Text] [Related]
6. Tracking myeloma tumor DNA in peripheral blood.
Waldschmidt JM; Vijaykumar T; Knoechel B; Lohr JG
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101146. PubMed ID: 32139012
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor cells for comprehensive and multiregional non-invasive genetic characterization of multiple myeloma.
Garcés JJ; Bretones G; Burgos L; Valdes-Mas R; Puig N; Cedena MT; Alignani D; Rodriguez I; Puente DÁ; Álvarez MG; Goicoechea I; Rodriguez S; Calasanz MJ; Agirre X; Flores-Montero J; Sanoja-Flores L; Rodriguez-Otero P; Rios R; Martinez-Lopez J; Millacoy P; Palomera L; Del Orbe R; Pérez-Montaña A; El Omri H; Prosper F; Mateos MV; Rosiñol L; Blade J; Lahuerta JJ; Orfao A; Lopez-Otin C; San Miguel JF; Paiva B;
Leukemia; 2020 Nov; 34(11):3007-3018. PubMed ID: 32475991
[TBL] [Abstract][Full Text] [Related]
8. Liquid Biopsy in Solid Malignancy.
Scarlotta M; Simsek C; Kim AK
Genet Test Mol Biomarkers; 2019 Apr; 23(4):284-296. PubMed ID: 30916594
[TBL] [Abstract][Full Text] [Related]
9. Refining Cancer Management Using Integrated Liquid Biopsy.
Qiu J; Xu J; Zhang K; Gu W; Nie L; Wang G; Luo Y
Theranostics; 2020; 10(5):2374-2384. PubMed ID: 32089746
[TBL] [Abstract][Full Text] [Related]
10. Novel Markers for Liquid Biopsies in Cancer Management: Circulating Platelets and Extracellular Vesicles.
Corvigno S; Johnson AM; Wong KK; Cho MS; Afshar-Kharghan V; Menter DG; Sood AK
Mol Cancer Ther; 2022 Jul; 21(7):1067-1075. PubMed ID: 35545008
[TBL] [Abstract][Full Text] [Related]
11. The Different Facets of Liquid Biopsy: A Kaleidoscopic View.
Eslami-S Z; Cortés-Hernández LE; Cayrefourcq L; Alix-Panabières C
Cold Spring Harb Perspect Med; 2020 Jun; 10(6):. PubMed ID: 31548226
[TBL] [Abstract][Full Text] [Related]
12. Extracellular vesicles as a source of prostate cancer biomarkers in liquid biopsies: a decade of research.
Ramirez-Garrastacho M; Bajo-Santos C; Line A; Martens-Uzunova ES; de la Fuente JM; Moros M; Soekmadji C; Tasken KA; Llorente A
Br J Cancer; 2022 Feb; 126(3):331-350. PubMed ID: 34811504
[TBL] [Abstract][Full Text] [Related]
13. The relevance of liquid biopsy in surgical oncology: The application of perioperative circulating nucleic acid dynamics in improving patient outcomes.
Jordan PR; O'Leary DP; Fleming CA; Wang J; Redmond HP
Surgeon; 2022 Aug; 20(4):e163-e173. PubMed ID: 34362650
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumour DNA sequence analysis as an alternative to multiple myeloma bone marrow aspirates.
Kis O; Kaedbey R; Chow S; Danesh A; Dowar M; Li T; Li Z; Liu J; Mansour M; Masih-Khan E; Zhang T; Bratman SV; Oza AM; Kamel-Reid S; Trudel S; Pugh TJ
Nat Commun; 2017 May; 8():15086. PubMed ID: 28492226
[TBL] [Abstract][Full Text] [Related]
15. Methods for the Detection of Circulating Biomarkers in Cancer Patients.
Mondelo-Macía P; Rodríguez-Ces AM; Suárez-Cunqueiro MM; Romay LM
Adv Exp Med Biol; 2022; 1379():525-552. PubMed ID: 35761006
[TBL] [Abstract][Full Text] [Related]
16. Utilising extracellular vesicles for early cancer diagnostics: benefits, challenges and recommendations for the future.
Pink RC; Beaman EM; Samuel P; Brooks SA; Carter DRF
Br J Cancer; 2022 Feb; 126(3):323-330. PubMed ID: 35013578
[TBL] [Abstract][Full Text] [Related]
17. Liquid Biopsy-Derived DNA Sources as Tools for Comprehensive Mutation Profiling in Multiple Myeloma: A Comparative Study.
Heestermans R; De Brouwer W; Maes K; Vande Broek I; Vaeyens F; Olsen C; Caljon B; De Becker A; Bakkus M; Schots R; Van Riet I
Cancers (Basel); 2022 Oct; 14(19):. PubMed ID: 36230824
[TBL] [Abstract][Full Text] [Related]
18. Nanoscale extracellular vesicle-derived DNA is superior to circulating cell-free DNA for mutation detection in early-stage non-small-cell lung cancer.
Wan Y; Liu B; Lei H; Zhang B; Wang Y; Huang H; Chen S; Feng Y; Zhu L; Gu Y; Zhang Q; Ma H; Zheng SY
Ann Oncol; 2018 Dec; 29(12):2379-2383. PubMed ID: 30339193
[TBL] [Abstract][Full Text] [Related]
19. Liquid biopsy in breast cancer: A comprehensive review.
Alimirzaie S; Bagherzadeh M; Akbari MR
Clin Genet; 2019 Jun; 95(6):643-660. PubMed ID: 30671931
[TBL] [Abstract][Full Text] [Related]
20. Liquid Biopsy: Current Status and Future Perspectives.
Mader S; Pantel K
Oncol Res Treat; 2017; 40(7-8):404-408. PubMed ID: 28693023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
